Alex Pasteur

Alex Pasteur is a Partner with F-Prime Capital. He is based in London and leads the firm’s biomedical investment efforts in Europe. He has worked in healthcare investing since 2001. Alex focuses on investments in therapeutics and healthcare IT, a portfolio that includes Orchard Therapeutics (NASDAQ: ORTX) where he was also a company founder, Adaptimmune Therapeutics (NASDAQ: ADAP), Acacia Pharma (BRU: ACPH), Arvelle Therapeutics (acquired by Angelini Pharma), Genomics PLC, Oviva AG, Owkin, Pulmocide Ltd and Nodthera Ltd.

Prior to joining F-Prime in 2012, Alex worked at MVM Life Science Partners LLP in the USA and Europe and was responsible for investments in Cara Therapeutics Inc. (NASDAQ: CARA), Vantia Ltd and Xention Pharma Ltd.

Alex earned a M.A. in Natural Sciences from Cambridge University and a Ph.D. in Chemistry from Cambridge University.